

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
12/15/1999	ROBERT-JAN ENZERINK	265280-64723	4338	
7590 01/13/2003				
M. HOPKINS, ESQ.		EXAM	EXAMINER	
LIFENET 7101 BLOOMSBURY LANE		PELLEGRINO, BRIAN E		
ANIA, VA 22553	•	APTIBUT	PAPER NUMBER	
		ART UNIT	PAPER NUMBER	
		3738		
		DATE MAILED: 01/13/2003	DATE MAILED: 01/13/2003	
	12/15/1999 7590 01/13/2003 M. HOPKINS, ESQ.	12/15/1999 ROBERT-JAN ENZERINK 7590 01/13/2003 M. HOPKINS, ESQ. MSBURY LANE	12/15/1999 ROBERT-JAN ENZERINK 265280-64723 7590 01/13/2003 M. HOPKINS, ESQ. MSBURY LANE ANIA, VA 22553 ART UNIT 3738	

Please find below and/or attached an Office communication concerning this application or proceeding.

-	<i>3</i> ~		E	
7	* *	Application No.	Applicant(s)	
	Advisory Action	09/461,829	ENZERINK ET AL.	
	•	Examiner	Art Unit	
		Brian E Pellegrino	3738	
	The MAILING DATE of this communication appe			
fina	E REPLY FILED 02 January 2003 FAILS TO PLACE refore, further action by the applicant is required to aval rejection under 37 CFR 1.113 may only be either: (1) addition for allowance; (2) a timely filed Notice of Appeal amination (RCE) in compliance with 37 CFR 1.114.	old abandonment of this applica) a timely filed amendment which I (with appeal fee); or (3) a timely	ation. A proper reply to a	
1		EPLY [check either a) or b)]		
b)	The period for reply expires 3 months from the mailing date The period for reply expires on: (1) the mailing date of this Anno event, however, will the statutory period for reply expire la ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	Advisory Action, or (2) the date set forth in a date set for the set for the set for the date se	g date of the final rejection. HE FINAL REJECTION. See MPEP	
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).				
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.				
2. The proposed amendment(s) will not be entered because:				
	(a) they raise new issues that would require further		ee NOTE below);	
1	(b) they raise the issue of new matter (see Note be	• •		
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or				
((d) ☐ they present additional claims without canceling NOTE:	g a corresponding number of fin	ally rejected claims.	
	Applicant's reply has overcome the following rejection			
	Newly proposed or amended claim(s) would be canceling the non-allowable claim(s).			
	The a) affidavit, b) whibit, or c) ≥ request for reapplication in condition for allowance because: See of	Continuation Sheet.		
	The affidavit or exhibit will NOT be considered becauraised by the Examiner in the final rejection.			
7.[_]	For purposes of Appeal, the proposed amendment(si explanation of how the new or amended claims would be appeared to the contraction of the contrac) a) will not be entered or b) lid be rejected is provided below] will be entered and an or appended.	
	The status of the claim(s) is (or will be) as follows:			
	Claim(s) allowed:			
	Claim(s) objected to:			
	Claim(s) rejected:			
_	Claim(s) withdrawn from consideration:			
	13 a/(
9.	Note the attached Information Disclosure Statement(s	s)(PTO-1449) Paper No(s)	<u></u> :	
	Other:			
C Datast	and Trademark Office			

Continuation of 5. does NOT place the application in condition for allowance because: the teaching that the Examiner is relying on in both 103 rejections is that the prosthetic graft of Dumican and the suture anchor of Li, both have sutures or suture material attached thereto and the entire device is packaged and sterilized. Both Dumican and Li teach a pre-assembled device ready for use once the package is opened for surgery. McGuire does disclose each and every element of the package or kit, i.e. see col. 5, lines 66,67 which discloses a fixation device. However, what the Examiner is relying on in both secondary references is that all elements of these devices are packaged and sterilized.

Bruce Snow Primary Examiner